摘要
目的探讨血管紧张素转化酶抑制剂治疗冠状动脉粥样硬化性心脏病(简称冠心病)的临床疗效。方法选取医院2021年10月至2022年5月收治的冠心病患者90例,按随机数字表法分为观察组和对照组,各45例。两组患者均予常规冠心病治疗药物(单硝酸异山梨酯+瑞舒伐他汀钙+阿司匹林)治疗,观察组加服血管紧张素转化酶抑制剂马来酸依那普利片,初期剂量为每次10 mg(每日1次),后根据患者病情调整剂量。结果观察组总有效率为93.33%,显著高于对照组的73.33%(P<0.05)。与对照组比较,观察组治疗后左室收缩末期内径、左心室舒张末期内径均显著降低,左心室射血分数显著升高,生活质量综合评定问卷(GQOL-74量表)评分显著升高(P<0.05)。结论血管紧张素转化酶抑制剂治疗冠心病,能改善患者心功能指标,提高生活质量。
Objective To investigate the clinical efficacy of angiotensin-converting enzyme inhibitors in the treatment of coronary atherosclerotic heart disease(CHD).Methods A total of 90 patients with CHD admitted to the hospital from October 2021 to May 2022 were selected and divided into the observation group and the control group according to the randomized number table method,with 45 cases in each group.Both groups were treated with conventional CHD drugs(isosorbide mononitrate+rosuvastatin calcium+aspirin),and the observation group was given angiotensin-converting enzyme inhibitor(Enalapril Maleate Tablet),with an initial dose of 10 mg per dose(once a day),and the dose was adjusted according to the patient's condition.Results The total effective rate in the observation group was 93.33%,which was significantly higher than 73.33%in the control group(P<0.05).Compared with those in the control group,the left ventricular end-systolic internal diameter and left ventricular end-diastolic internal diameter significantly reduced,the left ventricular ejection fraction significantly increased,and the score of the General Quality of Life Questionnaire(GQOL-74 scale)significantly increased in the observation group(P<0.05).Conclusion Angiotensin-converting enzyme inhibitors in the treatment of CHD can improve patients'cardiac function indexes and quality of life.
作者
缪琦
MIAO Qi(Wuhan Xinzhou District Red Cross Hospital•The Second Community Health Service Center of Zhucheng Street in Wuhan Xinzhou District,Wuhan,Hubei,China 431400)
出处
《中国药业》
CAS
2023年第S01期85-87,共3页
China Pharmaceuticals
